Third Harmonic Bio, Inc. (THRD)

Third Harmonic Bio, Inc. (THRD) — VMCI valuation read

Third Harmonic Bio, Inc. (THRD) carries a VMCI composite of 52/100, 2 points above the Healthcare sector median of 50. Among mid-cap names, that gap places THRD in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The THRD insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads THRD trades at 18.0x earnings, 0% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 3.3x is the binding constraint on the bear case, the line to track on Third Harmonic Bio, Inc.'s next 10-Q.

THRD rose 0.4% over the trailing 7 days, with a +6.2% read on a 30-day basis.